How ImmunityBio's (IBRX) Revenue Surge and Narrowed Losses May Affect Investor Outlook [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
This performance reflects a very large year-over-year increase in revenues and a reduction in losses, signaling operational progress for the company. We'll explore how ImmunityBio's surge in revenue growth and improved loss position shape its ongoing investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward What Is ImmunityBio's Investment Narrative? For ImmunityBio shareholders, the core belief centers on the company's ability to translate significant revenue acceleration and narrowing losses into sustainable growth through its experimental therapies and pipeline innovations. The recent surge in quarterly and nine-month revenues, up very sharply year over year, appears to reinforce confidence in ImmunityBio's commercial traction, especially for ANKTIVA, and may increase focus on upcoming regulatory or partnership catalysts. This operational progress is a shift from prior concerns about persistent losses and rapid cash b
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Slashes 9% on Lack of Leads [Yahoo! Finance]Yahoo! Finance
- A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]Seeking Alpha
- A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences [Yahoo! Finance]Yahoo! Finance
- Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Analyst Actions
- 9/10/25 - HC Wainwright
IBRX
Sec Filings
- 11/10/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- IBRX's page on the SEC website